Table 3 Univariate analyses of local control (LC) and radiation necrosis-free survival (RNFS) of the 52 lesions
Variable | Lesions (n) | 1 yr-LC (%) | p-value | 1 yr-RNFS (%) | p-value |
|---|---|---|---|---|---|
Gender | |||||
 Male | 33 | 95.7 |  | 84.3 |  |
 Female | 19 | 94.7 | 0.688 | 94.4 | 0.165 |
PTV margin | |||||
 2 mm | 24 | 100 |  | 86.3 |  |
 3 mm | 28 | 90.8 | 0.688 | 90.0 | 0.407 |
Targeted/immunotherapy (TT/IT) | |||||
 Concurrent | 36 | 100 |  | 90.0 |  |
 No/ sequential | 16 | 83.3 | 0.023 | 82.1 | 0.935 |
Concurrent TT/IT before SRS | |||||
 Yes | 21 | 91.4 |  | 78.3 |  |
 No | 31 | 100 | 0.197 | 86.9 | 0.723 |
Concurrent TT/IT after SRS | |||||
 Yes | 36 | 100 |  | 90.0 |  |
 No | 16 | 83.3 | 0.023 | 82.1 | 0.935 |
BRAF | |||||
 BRAF wild type | 27 | 91.5 |  | 91.6 |  |
 BRAF mutation | 25 | 100 | 0.189 | 81.9 | 0.151 |
Melanoma-molGPA | |||||
 0.5–1.0 | 3 | 0 |  | 50.0 |  |
 1.5–2.0 | 27 | 100 |  | 90.9 |  |
 2.5–3.0 | 16 | 100 |  | 91.7 |  |
 3.5–4.0 | 6 | 100 | < 0.001 | 83.3 | 0.147 |
V10 | |||||
≤ 12 ccm | 40 | 94.6 |  | 94.4 |  |
> 12 ccm | 12 | 100 | 0.55 | 37.0 | < 0.001 |
V12 | |||||
≤ 10 ccm | 41 | 94.8 |  | 91.7 |  |
>Â 10 ccm | 11 | 100 | 0.587 | 70.0 | 0.004 |